A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke

Amarenco, Pierre; Js, Kim; Labreuche, Julien; Charles, Hugo; Abtan, Jérémy; Béjot, Yannick; Cabrejo, Lucie; Cha, Jihoon; Ducrocq, Grégory; Giroud, Maurice; Guidoux, Céline; Hobeanu, Cristina; Kim, Yoon Jun; Lapergue, Bertrand; Pc, Lavallée; Bc, Lee; Kb, Lee; Leys, Didier; Mh, Mahagne; Meseguer, Elena; Nighoghossian, Norbert; Pico, Fernando; Samson, Yves; Sibon, Igor; Pg, Steg; Sm, Sung; Touboul, Pierre‐Jean; Touzé, Emmanuel; Varenne, Olivier; Vicaut, Éric; Yelles, Nessima; Bruckert, Éric

doi:10.1056/nejmoa1910355

Cited by 372 publications

(293 citation statements)

References 15 publications

Supporting

Mentioning

266

Contrasting

Unclassified

Order By: Relevance

“…A randomised parallel-group event-driven study assigned a total of 2860 patients with a recent (less than 3 months) ischaemic stroke or a TIA (less than 15 days) to a target LDL-C level of below 1.8 mmol/l (lower-target group, n = 1430) or to a target range of 2.3-2.8 mmol/l (higher-target group, n = 1430) [76]. All patients enrolled had either ECAS, ICAS, atherosclerotic plaques of the aortic arch (4 mm or larger) or a known history of coronary artery disease.…”

Section: Dyslipidaemiamentioning

confidence: 99%

Intracranial Atherosclerotic Stenoses: Pathophysiology, Epidemiology, Risk Factors and Current Therapy Options

et al. 2020

View full text Add to dashboard Cite

Intracranial atherosclerotic stenoses (ICAS) are one of the most common causes of first and recurrent cerebrovascular ischaemic events worldwide, with highest prevalence in Asian, Hispanic and African populations. Clinical trials have improved the understanding of epidemiology, risk factors and imaging characteristics of patients with ICAS. Current therapeutic approaches concerning these patients include management of risk factors, best medical therapy, potentially endovascular and rarely surgical therapy. In our review, we elucidate the current epidemiology and evidence in evaluation of risk factors and therapeutic options for providing favourable outcome for patients with ICAS.

show abstract

Section: Dyslipidaemiamentioning

confidence: 99%

Intracranial Atherosclerotic Stenoses: Pathophysiology, Epidemiology, Risk Factors and Current Therapy Options

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Yakın zamanda yapılan bir çalışmada da yoğun statin tedavisinin düşük yoğunluklu statin tedavisine göre iskemik inme, miyokard enfarktüsü, koroner veya karotis revaskülarizasyonu veya kardiyovasküler ölümden oluşan birincil sonlanım noktalarında anlamlı olarak üstün olduğunu göstermiştir. [29] Sonuç olarak serebrovasküler hastalık geçirmiş hastalarda statin tedavisini değiştirmeye gerek yoktur, hasta açısından net fayda statinler lehinedir.…”

Section: Hemorajik Inmeunclassified

Statin Intolerance

Başaran¹

2020

updates cardiol

View full text Add to dashboard Cite

20The importance of lipid lowering therapies has increased with the precise determination of the causal relationship of cholesterol with atherosclerosis. Especially the need for long-term statin use (the most effective and safest drugs to lower low density lipoprotein (LDL) cholesterol) has led to serious investigations regarding the side effects of statins. The most important side effects of statins are myopathy, new onset diabetes, and despite some conflicting results hemorrhagic stroke. The most common side effect is myopathy and it is the most common cause for statin discontinuation. This condition is also known as statin intolerance and is associated with increased cardiovascular events rate. Threfore, management strategies of this problem are becoming increasingly important. In this article, statin side effects are reviewed briefly and management strategies of statin side effects are summarized with a special focus on patients with myopathy. ABSTRACTKolesterolün ateroskleroz ile nedensel ilişkisinin kesin olarak saptanmasıyla lipit düşürücü tedavilerin önemi artmıştır. Özellikle düşük dansiteli lipoprotein (LDL) kolesterol üzerine en etkili ve en güvenilir ilaçlar olan statinlerin uzun süre kullanmanın gerekliliği bu ilaçların olası yan etkilerinin ciddi şekilde araştırılmasına yol açmıştır. Statinlerin en önemli yan etkileri miyopati, yeni diyabet gelişimi ve çelişkili çalışma sonuçları olmakla birlikte hemorajik inme olarak öne çıkmaktadır. Klinik pratikte en sık görülen yan etki olan miyopati statin kesilmesinin en sık nedenidir. Statin intoleransı olarak da adlandırılan bu durum artmış kardiyovasküler olay riski ile ilişkilidir ve bu sorunla başa çıkma yolları giderek daha fazla önem kazanmaktadır. Bu yazıda statin yan etkileri kısaca gözden geçirilmiş ve özellikle miyopati gelişen hastalara odaklanılarak statin yan etkileri ile başa çıkma stratejileri özetlenmiştir.Anahtar sözcükler: Ateroskleroz; statin; myopati; statin intoleransı.

show abstract

“…Hier war die Risikoreduktion mit 26 % sogar noch ausgeprägter. In der kürzlich publizierten "Treat Stroke to Target"-Studie wurde in einem randomisierte Parallelgruppenvergleich 2 Zielbereiche des LDL-Cholesterins (< 70 mg/dl vs. 90-110 mg/dl) bei Patienten mit rezentem Schlaganfall und zerebrovaskulärer oder koronararterieller Arteriosklerose verglichen [9]. Auch wenn die Studie aus administrativen Gründen frühzeitig abgebrochen werden musste, ergab sich dennoch ein signifikanter Vorteil für Patienten mit intensiverer LDL-Cholesterinabsenkung.…”

Section: Hyperlipidämieunclassified

Sekundärprophylaxe der zerebralen Ischämie

Reiff¹,

Ringleb²

2020

Nervenheilkunde

View full text Add to dashboard Cite

ZUSAMMENFASSUNGDie Sekundärprävention von Hirninfarkt und TIA umfasst neben wichtigen Maßnahmen der Lebensstiländerung zur Risikofaktorenmodifikation verschiedene medikamentöse und interventionelle Verfahren. Durch Behandlung von arterieller Hypertonie und Hyperlipidämie können erneute vaskuläre Ereignisse, Schlaganfall wie Herzinfarkt, verhindert werden. Eine große Bedeutung hat auch die antithrombotische Sekundärprävention durch Thrombozytenaggregationshemmer und orale Antikoagulantien sowie deren Kombination. Bei Vorliegen symptomatischer intra- oder extrakranieller arteriosklerotischer Stenosen können auch gefäßchirurgische oder neuroradiologisch interventionelle Verfahren der Verhinderung weiterer Schlaganfälle dienen.

show abstract

A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke

Cited by 372 publications

References 15 publications

Intracranial Atherosclerotic Stenoses: Pathophysiology, Epidemiology, Risk Factors and Current Therapy Options

Intracranial Atherosclerotic Stenoses: Pathophysiology, Epidemiology, Risk Factors and Current Therapy Options

Statin Intolerance

Sekundärprophylaxe der zerebralen Ischämie

Contact Info

Product

Resources

About